What a $312,000 Kestra Insider Sale Signals After 25% Stock Gains
This cardiac device innovator saw a notable insider sale, as routine portfolio moves continue amid its push in digital health solutions.
What a $312,000 Kestra Insider Sale Signals After 25% Stock Gains
Overview
On June 15, 2026, Brian Daniel Webster reported the direct sale of 15,000 common shares of Kestra Medical Technologies, Ltd. (NASDAQ:KMTS), according to a SEC Form 4 filing.
Transaction value based on SEC Form 4 weighted average purchase price ($20.81).
Details
Kestra Medical Technologies operates at the forefront of digital and wearable healthcare, focusing on advanced cardiovascular monitoring and intervention solutions. The company's integrated approach leverages both proprietary medical devices and connected digital services to support high-risk cardiac patients. This combination of technology and services positions Kestra to address critical needs in patient care and provider engagement within the cardiovascular space.
Source
Originally published at www.fool.com.
